Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

January 17, 2020January 17, 2020

IMU-856 Restores Gut Barrier Function, Key for Halting IBD Progression, Preclinical Data Suggests

News

The oral small molecule IMU-856, now being developed by Immunic Therapeutics, strengthens and improves the barrier function of intestinal cells while having little to no effect on the immune system, ... Read more

January 15, 2020January 15, 2020

Prevalence of Mental Health Problems Rising Among Veterans with IBD, Study Reveals

News

The prevalence of anxiety, depression and post-traumatic stress disorder (PTSD) is increasing in U.S. veterans with inflammatory bowel disease (IBD), according to a retrospective study. Meanwhile, the risk for ... Read more

January 10, 2020January 10, 2020

Prevalence of Ulcerative Colitis in the US Remains Stable at 1%, Survey Data Show

News

The prevalence of ulcerative colitis remained stable in the United States from 1976 to 2010, affecting 1% of the population, according to a survey analysis. The study also found ... Read more

December 20, 2019December 20, 2019

Vaccine Against Bacterial Protein May Lessen Gut Inflammation, Mouse Study Indicates

News

Vaccinating against flagellin, a protein involved in the movement of certain bacteria, lessened inflammation in the gut, a study of mice shows. These findings suggest that vaccination against certain ... Read more

December 6, 2019December 17, 2019

Therapeutic Targeting of MT1-MMP Protein May Help Halt IBD Progression, Study Suggests

News

The membrane type 1-matrix metalloproteinase (MT1-MMP) protein may be a promising therapeutic target for inflammatory bowel disease (IBD) — possibly targeting the disease in its early stages, a study ... Read more

October 22, 2019October 22, 2019

Stelara Approved in US to Treat Moderate-to-Severe Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of adults with ulcerative colitis (UC) that is moderately to severely active, Janssen Pharmaceuticals, Stelara’s developer ... Read more

August 23, 2019August 23, 2019

Landos Biopharma Secures $60M Financing, Continues BT-11 Development for IBD

News

Landos Biopharma’s investigational BT-11 therapy for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is continuing testing in Phase 2 clinical trials — some of which ... Read more

July 12, 2019July 12, 2019

Th17 Immune Cells Raise Risk of Severe C. difficile in Colitis Patients, Study Shows

News

Patients with colitis are particularly susceptible to infection by the toxin-producing bacteria Clostridium difficile, but the reason remained unknown. Now, researchers have discovered that changes in the immune system, ... Read more

June 26, 2019June 26, 2019

Youngsters Diagnosed with IBD Have Increased Cancer Risk, Study Contends

News

Inflammatory bowel disease (IBD) diagnosis during childhood or adolescence may be linked with an increased risk for developing cancer, compared to the general population, according to results of a ... Read more

June 21, 2019June 21, 2019

First Patient Dosed in Phase 3 Trial of Etrasimod for Moderate to Severe UC

News

The Phase 3 trial ELEVATE UC 52 evaluating Arena Pharmaceuticals’ investigational therapy etrasimod for patients with moderately to severely active ulcerative colitis has dosed its first patient. “We are pleased ... Read more